Navigation Links
Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
Date:3/8/2010

DENVER, March 8 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: CHYE) is pleased to announce today that the Company has retained California-based Redwood Consultants, LLC to assist in shareholder relations and investor communications.

Ampio Pharmaceuticals, Inc. CEO Don Wingerter said, "We are delighted to announce our relationship with Redwood Consultants. We are committed to providing timely and consistent updates to the investment community. We will be working closely with senior management of Redwood to keep the global investment community apprised of our progress at all levels."

Redwood Consultants Managing Director, Jens Dalsgaard commented, "We believe Ampio has the potential to be a billion dollar company. Their strong product pipeline and seasoned management team can provide investors significant milestones both near and long term. With several hundred discoveries and high quality research capabilities, Chief Scientific Officer Dr. Bar-Or has over 80 publications in referenced Journals, over 50 published patents and 119 patent applications. The Ampio team has uncovered a range of discoveries beneficial to many areas of medical practice including diagnostic medicine, immune therapy, diabetes, particularly diabetic retinopathy, neurology, cardiology and oncology. We are elated to be working with Ampio and look forward to frequent investor updates."

About Redwood Consultants, LLC

Redwood Consultants, LLC is a full-service investor relations firm that works closely with emerging, publicly traded companies to communicate their value to the investment community and build and sustain greater investor sponsorship. We are committed to our clients' success. Our mission is to deliver highly credible information and comprehensive research on the corporate potential of the emerging companies we represent to the Wall Street community of analysts, institutional investors and retail stockbrokers. Redwood Consultants recognizes that small, innovative companies must align themselves with a trusted investor relations partner to successfully compete in today's new-market environment. We are known throughout the financial community for our loyalty, integrity and credibility. For more information, see www.redwoodconsultants.com.

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc is a Denver based bio technology firm with a long relationship with the Swedish Medical Center.  With several hundred discoveries, high quality research capabilities and access to extensive clinical data, Ampio is developing exciting pharmaceutical products and medical devices.

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

SOURCE Ampio Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.ampiopharma.com

'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
2. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
3. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
6. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
7. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
8. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
9. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
10. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
11. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – ... but be heartened by the industry’s current surge. But another thing that unifies them ... At last they can simply, safely and effectively end their aroma anguish thanks ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
(Date:4/24/2017)... ... , ... Michael Vick announced his retirement earlier this year from the NFL ... one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro ... career rushing yards by a quarterback (6,109) and the most rushing yards by a ...
Breaking Medicine News(10 mins):